Cambridge Investment Research Advisors, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 87,984 shares of RXRX stock, worth $511,187. This represents 0.0% of its overall portfolio holdings.
Number of Shares
87,984
Previous 79,583
10.56%
Holding current value
$511,187
Previous $524,000
13.55%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding RXRX
# of Institutions
341Shares Held
284MCall Options Held
2.83MPut Options Held
3.64M-
Vanguard Group Inc Valley Forge, PA34MShares$198 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$188 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$144 Million0.13% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$101 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$85.2 Million0.44% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.05B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...